Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2023 17:30 ET | Source: Coherus BioSciences, Inc.

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in...
June 01, 2023 08:33 ET | Source: Coherus BioSciences, Inc.

Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients

– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company – – YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and...
June 01, 2023 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023

REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023*...
May 22, 2023 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

– UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – – UDENYCA® AI fulfills high unmet need...
May 16, 2023 06:50 ET | Source: Coherus BioSciences, Inc.

Coherus Prices Public Offering of Common Stock

REDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its...
May 15, 2023 16:01 ET | Source: Coherus BioSciences, Inc.

Coherus Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of...
May 08, 2023 16:05 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –– FDA inspection of...
May 04, 2023 16:30 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences to Present at Upcoming Investor Conferences in May

REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor...
May 01, 2023 16:07 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market...
April 27, 2023 08:05 ET | Source: Coherus BioSciences, Inc.

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....